Lyell Immunopharma - LYEL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.00
  • Forecasted Upside: 133.92%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.71
▲ +0.01 (0.59%)

This chart shows the closing price for LYEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lyell Immunopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LYEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LYEL

Analyst Price Target is $4.00
▲ +133.92% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lyell Immunopharma in the last 3 months. The average price target is $4.00, with a high forecast of $6.00 and a low forecast of $1.00. The average price target represents a 133.92% upside from the last price of $1.71.

This chart shows the closing price for LYEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Lyell Immunopharma. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/14/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/27/2024Bank of AmericaLower TargetBuy ➝ Buy$9.00 ➝ $6.00Low
6/27/2024HC WainwrightReiterated RatingBuy ➝ Neutral$6.00 ➝ $1.00Low
5/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
2/29/2024HC WainwrightLower TargetBuy ➝ Buy$8.00 ➝ $6.00Low
11/9/2023HC WainwrightLower TargetBuy ➝ Buy$9.00 ➝ $8.00Low
8/28/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$15.00 ➝ $5.00Low
3/2/2023HC WainwrightLower TargetBuy$11.00 ➝ $9.00Low
1/24/2023Morgan StanleyLower TargetEqual Weight$7.00 ➝ $4.00Low
11/14/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$15.00 ➝ $7.00Low
11/11/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$13.00 ➝ $7.00Low
11/9/2022HC WainwrightLower Target$12.00 ➝ $11.00Low
10/17/2022HC WainwrightInitiated CoverageBuy$12.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$21.00 ➝ $12.00Low
3/31/2022The Goldman Sachs GroupLower TargetBuy$31.00 ➝ $21.00High
1/6/2022Morgan StanleyLower TargetOverweight$25.00 ➝ $20.00Low
7/12/2021JPMorgan Chase & Co.Initiated CoverageOverweight$22.00Medium
7/12/2021Morgan StanleyInitiated CoverageOverweight$25.00Low
7/12/2021Bank of AmericaInitiated CoverageBuy$25.00Low
7/12/2021The Goldman Sachs GroupInitiated CoverageBuy$30.00Low
(Data available from 7/15/2019 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/17/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/16/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/17/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/16/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/16/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/15/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/15/2024

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Lyell Immunopharma logo
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $1.71
Low: $1.65
High: $1.77

50 Day Range

MA: $2.25
Low: $1.31
High: $2.78

52 Week Range

Now: $1.71
Low: $1.18
High: $3.41

Volume

498,500 shs

Average Volume

1,012,150 shs

Market Capitalization

$435.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Lyell Immunopharma?

The following Wall Street research analysts have issued stock ratings on Lyell Immunopharma in the last year: Bank of America Co., HC Wainwright, and JPMorgan Chase & Co..
View the latest analyst ratings for LYEL.

What is the current price target for Lyell Immunopharma?

3 Wall Street analysts have set twelve-month price targets for Lyell Immunopharma in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 133.9%. Bank of America Co. has the highest price target set, predicting LYEL will reach $6.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.00 for Lyell Immunopharma in the next year.
View the latest price targets for LYEL.

What is the current consensus analyst rating for Lyell Immunopharma?

Lyell Immunopharma currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in LYEL, but not buy more shares or sell existing shares.
View the latest ratings for LYEL.

What other companies compete with Lyell Immunopharma?

How do I contact Lyell Immunopharma's investor relations team?

The company's listed phone number is 650-695-0677 and its investor relations email address is [email protected]. The official website for Lyell Immunopharma is www.lyell.com. Learn More about contacing Lyell Immunopharma investor relations.